-
Featured
Vaginal Estradiol, Moisturizer No Better Than Placebo for Postmenopausal Vulvovaginal Symptoms
Neither a prescription vaginal estradiol tablet nor an over-the-counter vaginal moisturizer provides additional benefit over dual placebo in reducing postmenopausal vulvovaginal symptoms, according to the first randomized comparison.
-
Featured
New Questionnaire Aims to Increase Understanding and Treatment of Menopause Symptoms
A new patient-reported outcome measure, the Vulvovaginal Atrophy Questionnaire, aims to improve clinicians' understanding of the extent and impact of genitourinary symptoms of menopause on women.
-
Featured
Evaluating Post-Menopausal Women's Vulvovaginal Symptoms, Mood and Sex Life
These pioneering studies from Massachusetts General Hospital evaluate the efficacy of two common, low-risk treatments for postmenopausal symptoms against a placebo and assess how much postmenopausal women were bothered by vulvovaginal discomfort symptoms, along with their impact on mood and quality of life.
-
After Denosumab Discontinuation, Alendronate Superior to Raloxifene at Maintaining BMD Gains
Massachusetts General Hospital researchers found that for postmenopausal women with osteoporosis who discontinue short-term denosumab treatment and are unable or unwilling to transition to a bisphosphonate, raloxifene may be a suitable alternative, although inferior in maintaining the gain in bone mineral density.
-
Medical Grand Rounds: Multidisciplinary Cases From Pregnancy to Menopause
In a recent Medical Grand Rounds presentation led by the Women's Health and Sex and Gender-based Medicine Program at Massachusetts General Hospital, a multidisciplinary panel presented several cases across a woman's reproductive lifespan, from pregnancy to menopause.
-
Lipoprotein(a) Prognostic of CHD in Contemporary Cohort Receiving Menopausal Hormone Therapy
Michael C. Honigberg, MD, MPP, Pradeep Natarajan, MD, MMSc, and Mark Trinder, MSc, studied 88,266 participants in the UK Biobank and found no evidence that contemporary menopausal hormone therapy reduces the lipoprotein(a)-associated risk of coronary heart disease.
Menopause Contributors
-
Caroline M. Mitchell, MD, MPH
Director, Vulvovaginal Disorders Program, Chair, DEI Committee, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
Recent Article
Commentary: Transcending Language Barriers in Obstetrics and Gynecology
-
Jan Shifren, MD
Director, Massachusetts General Hospital Midlife Women's Health Center, Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
Recent Article
Taking a Multidisciplinary Approach to Menopause
Obstetrics & Gynecology Care at Mass General
The Mass General Department of Obstetrics & Gynecology offers the highest level of care to women. Our clinical and research team is a leader in advancing treatments for gynecologic cancers, menopause, high-risk obstetrics, infertility and urogynecology.